This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Gemin X ) Identifier:
First received: December 1, 2006
Last updated: July 19, 2016
Last verified: July 2016
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

Condition Intervention Phase
Mantle-Cell Lymphoma Drug: Obatoclax mesylate Drug: Bortezomib Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries ( Gemin X ):

Primary Outcome Measures:
  • Determine the response rate to obatoclax in combination with Bortezomib and characterize the safety profile [ Time Frame: 4 weeks to 2 years ]

Secondary Outcome Measures:
  • Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusion and growth factor requirements [ Time Frame: 4 weeks to 2 years ]

Enrollment: 24
Study Start Date: October 2006
Study Completion Date: November 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
30mg obatoclax, 1.0mg/m2 bortezomib
Drug: Obatoclax mesylate
30 mg, 45 mg
Other Name: (GX15-070MS)
Drug: Bortezomib
1.0mg/m2, 1.3 mg/m2
Experimental: 2
obatoclax 30 mg, bortezomib 1.3 mg/m2
Drug: Obatoclax mesylate
30 mg, 45 mg
Other Name: (GX15-070MS)
Drug: Bortezomib
1.0mg/m2, 1.3 mg/m2
Experimental: 3
Obatoclax 45 mg, Bortezomib 1.3 mg/m2
Drug: Obatoclax mesylate
30 mg, 45 mg
Other Name: (GX15-070MS)
Drug: Bortezomib
1.0mg/m2, 1.3 mg/m2

Detailed Description:
This is a multi-center, open-label, Phase I study of Obatoclax administered in combination with bortezomib in 3-week cycles to patients with relapsed or refractory Mantle Cell Lymphoma. Treatment may be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described herein may be administered with the intent to treat the patients's malignancy. Supportive care measures including those directed at controlling symptoms resulting from Mantle Cell Lymphoma are allowed.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathological confirmation of Mantle Cell Lymphoma (ML)
  • Must have documented relapse or progression following 1 or 2 prior lines of antineoplastic therapy
  • Must have normal organ function
  • Must have the ability to understand and willingness to sign a written informed consent form

Exclusion Criteria:

  • No other agents or therapies administered with the intent to treat malignancy
  • Patients with prior exposure to obatoclax
  • Uncontrolled, intercurrent illness
  • Pregnant women and women who are breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00407303

United States, Georgia
NW Georgia Oncology Centers
Marietta, Georgia, United States, 30060
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Roswell Park Medical Center
Buffalo, New York, United States, 14263
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Gemin X
Study Director: Jean Viallet, MD Gemin X, Inc.
  More Information

Responsible Party: Gemin X Identifier: NCT00407303     History of Changes
Other Study ID Numbers: GEM012
Study First Received: December 1, 2006
Last Updated: July 19, 2016

Additional relevant MeSH terms:
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents processed this record on August 18, 2017